. 2014 Dec 18;9:199. doi: 10.1186/s13023-014-0199-0

Table 5.

Proportion of non-deteriorated patients (Full Analysis Set, n = 80)

	Placebo ( n = 19)	PXT3003 LD ( n = 21)	PXT3003 ID ( n = 21)	PXT3003 HD ( n = 19)	HD *versus* Placebo		HD *versus* PLI
Non-deteriorated	10 (52%)	10 (48%)	9 (43%)	15 (79%)	Relative Risk	P-value	Relative Risk	P-value
Non-deteriorated	10 (52%)	10 (48%)	9 (43%)	15 (79%)	1.5 (1.03;1.77)	0.047*	1.66 (1.24;1.93)	0.010*

Data are count (%) of non-deteriorated patients per group and Relative Risks (90% CI) for the HD group versus Placebo and versus PLI assessed with a logistic regression model. P-values are one-tailed. *P < 0.05.